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Abstract
Introduction: Behcet’s disease (BD) is a multi-systemic disorder with muco-cutaneous, ocular, arthritic, vascular or
central nervous system involvement. The role of gδ T cells is implicated in BD. The activation status of gδ T cells
and their cytokine secretion against phosphoantigens are evaluated in BD.
Methods: NKG2A, NKG2C, NKG2D, CD16 and CCR7 molecules on gδ T cells were analyzed in 70 BD, 27 tuberculosis
(TB) patients and 26 healthy controls (HC). Peripheral gδ T cells were expanded with a phosphoantigen (BrHPP) and
IL-2, restimulated with BrHPP and a TLR3 ligand, and cytokine production was measured.
Results: gδ T cells were not increased in both BD and TB patients, but the proportions of TCRVδ2+ T cells were lower
(58.9 and 50.7 vs. 71.7%, P = 0.04 and P = 0.005) compared to HC. Higher proportion of TCRVδ2+ T cells were CD16+
(26.2 and 33.9 vs. 16.6%, P = 0.02 and P = 0.001) and CCR7- (32.2 and 27.9 vs. 17.7%, P < 0.0001 and P = 0.014) in BD and
TB patients compared to HC. NKG2C+ gδ+ T cells were relatively increased (0.5 and 0.6 vs. 0.3%, P = 0.008 and 0.018),
whereas NKG2D positivity was decreased in patients with BD and TB (77.7 and 75.8 vs. 87.5%, P = 0.001 and 0.004).
Expansion capacity of gδ T cells in BD and TB as well as production of IL-13, IFN-g, granulocyte monocyte colony
stimulating factor (GM-CSF), TNF-a, CCL4 and CCL5 in BD was lower compared to HC, when restimulated by TLR3
ligand and BrHPP.
Conclusion: The changes on gδ T cells of BD as well as TB patients implicate that gδ T cells have already been
exposed to regulatory effects, which changed their activity. Lower cytokine response of gδ T cells implicates down
modulation of these cells in BD.
Introduction
Behcet’s disease (BD) is a systemic inflammatory disorder
with a diverse spectrum of clinical manifestations includ-
ing mucocutaneous, ocular, vascular, gastro-intestinal,
musculoskeletal and central nervous system involvements.
A complex genetic background leading to a pro-inflamma-
tory, innate immune system derived activation perpetuated
by adaptive immune responses against environmental or
auto-antigens is considered as the pathogenic mechanism
in BD [1-3].
gδ T cells represent a minor T cell population (1 to 10%
of peripheral blood (PB) T cells) with combining proper-
ties of adaptive and innate immunity that express T cell
receptors (TCRs) comprised of g and δ heterodimer.
TCRVg9Vδ2+ T cells, the major subset of gδ T cells (70 to
95%) in the PB in humans, recognize non-peptidic phos-
phoantigens produced by microbial and eukaryotic meva-
lonate pathways in a TCR-dependent manner [4]. In
adults with negative purified protein derivative (PPD)
response, TCRVg9Vδ2+ T cells reacting to isopentenyl
pyrophosphate (IPP) secrete Th1 type cytokines (IFN-g,
TNF-a) and MIP-1b (CCL4) [5]. TCRVg9Vδ2+ T cells sti-
mulated in the presence of growth factors and cytokines
can produce abundant amounts of the pro-inflammatory
cytokines and change their phenotype from memory cells
expressing CCR7+ to CCR5+ expressing cells [6].
The low affinity immunoglobulin receptor (FcgRIII)
CD16 is also shown to discriminate between two subsets
of TCRVg9Vδ2+ T cells with distinct functional responses
[7]. The expression of CD16 regulated cytolytic activity
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and production of inflammatory cytokines of the gδ T
cells.
gδ T cells also express inhibitory and activating members
of the NK receptor family and modulate their effector
functions, such as cytotoxicity and cytokine production.
Among the NK receptors, heterodimeric “killer lectin
receptors” of CD94 with NKG2A or NKG2C, exerting
inhibitory or activating effects, respectively, interact with
the nonclassical MHC class Ib molecule HLA-E [8]. The
majority of TCRVg9Vδ2+ T cells harbor inhibitory recep-
tors with CD94/NKG2A heterodimers and these cells
exhibit a strong lytic activity [9].
Due to their small number in the peripheral blood,
human gδ T cells are often expanded before functional
studies are performed. Short-term gδ T cells can be gener-
ated from PB by stimulating with gδ T cell specific phos-
phoantigens and IL-2 in vitro. Depending on the stimulus
and IL-2, purity of these cells may reach up to 70 to 95%
[10]. As these expanded human gδ T cells are shown to
express mRNA of TLR1-10 receptors similar to freshly
isolated gδ T cells, costimulatory effects of TLR ligands
could be demonstrated in vitro [11,12].
Peripheral blood gδ T cells were elevated in BD, with a
polyclonal activation [13,14]. gδ T cells were associated
with active BD with higher expression of CD69 and
production of IFN-g and TNF-a [15]. IPP-specific
TCRVg9Vδ2+ Th1-like cells from intra-ocular fluid are
generated from the eye of BD patients with uveitis [16].
In Italian BD patients, TCRVg9δ2+ T lymphocytes were
expanded and shown to express TNF receptor II and
IL-12 receptor b1 in active disease [17].
A more prominent pro-inflammatory cytokine secre-
tion was shown from peripheral blood mononuclear cells
(PBMCs) in BD patients in response to various antigens,
including IPP and PPD, and increased IFN-g and IL-12
secretion was detected [18]. In this study, ex vivo PBMC
are studied to evaluate gδ T cells as a candidate for an
immune effector cell group in BD, in tuberculosis (TB) as




The patient group consisted of 70 patients with Behçet’s
disease (48 men and 22 women, mean age 36.8 ±
11.0 years), followed at the BD Outpatient Clinic of the
Division of Rheumatology, Istanbul Faculty of Medicine,
Istanbul University. All patients met the International
Study Group criteria for the classification of BD [19].
Active disease was defined as the presence of ongoing
disease activity depending on the assessment of any
exacerbation of characteristic BD symptoms within the
last four weeks or at the first visit, including severe skin,
mucosal and/or ocular manifestations that required
introduction or increase of systemic corticosteroids (Table
1). At the time of blood sampling, disease was active in
38 patients. Of the active patients, 36 were using colchi-
cine, 24 of them were using immunosuppressant agents,
such as azathioprine (n = 13) or corticosteroids (n = 19),
and 2 patients were untreated. Seven inactive patients were
using only colchicine and 25 patients were on colchicine as
well as an immunosuppressant agent, such as azathioprine
(n = 13) and low or medium dose corticosteroids (n = 14).
Twenty-seven active TB patients (20 men and 7 women,
mean age 37.0 ± 15.7 years) and 26 healthy volunteers
(HC, 22 men and 4 women, mean age 38.1 ± 9.5 years)
were enrolled as control groups. Ethics Committee of
Istanbul Faculty of Medicine approved the study protocol,
and all study donors provided written informed consent
according to the Declaration of Helsinki prior to blood
collection.
Cell preparation - flow cytometry
PBMCs were isolated from EDTA- anticoagulated venous
blood by density-gradient centrifugation (Lymphoprep,
Eurochrom, Berlin, Germany). Fluorescence-conjugated
monoclonal antibodies (mAb) and their target antigens
used in the study were as follows: CD45/FITC (fluorescein
isothiocyanate)-CD14/R-PE (R-phycoerythrin) (Ancell
Corporation, Bayport, MN, USA), CD16/PC5 (anti-
FcgRIII, 368), CD56/PC5 (anti-NCAM, N901), pan-gδ/
FITC (Immu510), δ2/FITC (Immu389), CD8/PC5 (B9.11),
NKG2D/PE (ON72), NKG2A/PE (Z199, Beckman-Coul-
ter, Immunotech, Marseille Cedex, France), CD94/FITC
(70 kDa dimer, Kp43, HP-3D9, BD Biosciences, USA),
NKG2C/PE (134591) and CCR7/PE (150503, R&D
Systems, USA). For every antibody combination, 1 μl of
antibody per 105 PBMCs was incubated at 4°C for 20 min-
utes, washed and analyzed by flow cytometer (Epics XL,
Beckman-Coulter, USA). Results are expressed as percen-
tages of the respective positive cells in the lymphocyte gate.
In vitro expansion of TCRVg9Vδ2+ T lymphocytes
PBMCs were cultured in 96-well plates at a concentra-
tion of 106 cells/ml in RPMI 1640 supplemented with
Table 1 Clinical features of 70 BD patients with active (A-
BD) and inactive disease (IA-BD)





Oral ulcer 22 (57.9) 23 (71.9)
Genital ulcer 13 (34.2) 9 (28.1)
Skin manifestations 21 (55.3) 24 (75)
Pathergy 8 (21.1) 15 (46.9)
Joint manifestations 14 (36.8) 7 (21.9)
Uveitis 6 (15.8) 4 (12.5)
Vascular manifestations 11 (28.9) 7 (21.9)
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10% fetal calf serum (Gibco, Life Technologies, USA),
2 mM L-glutamine, 1% sodium pyruvate and 100 U/ml
penicillin/streptomycin (Sigma, Deisenheim, Germany) at
37°C and 5% CO2. The proportion of gδ T cells was mea-
sured on the first day. For the expansion of TCRVg9Vδ2+
T cells, PBMCs were cultured in medium alone or in the
presence of a synthetic analogue of natural phosphoanti-
gens (bromohydrin pyrophosphate, BrHPP, 3 mM, kindly
provided by Helene Sicard, Innate Pharma, Marseille,
France). Responsive gδ T cells were expanded by adding
100 IU/ml recombinant human interleukin-2 (IL-2) on the
second and fifth day of the cell culture. After eight days,
cells were washed and expansion of TCRVg9Vδ2+ T cells
was assessed by staining the cultured cells with anti-
TCRVδ2 (Immu389), as described above. Cultures of
donors with at least 70% gδ+ (TCRVδ2+) T cells (23 active
BD, 20 inactive BD, 9 TB, 20 HC) were restimulated with
the 50 mg/ml Polyinosinic:polycytidylic acid (PolyI:C,
TLR3 agonist), 3 mM BrHPP or PolyI:C and BrHPP at the
eighth day. The levels of IL-13, interferon-g (IFN-g), tumor
necrosis factor-a (TNF-a), granulocyte monocyte colony
stimulating factor (GM-CSF), CCL4 (macrophage inflam-
matory protein 1-b) and CCL5 (RANTES, Regulated
on Activation, Normal T Expressed and Secreted) were
measured in the supernatants after 24 hours of the re-
stimulation by multiplex ELISA (Procarta, Luminex,
Affymetrix, CA, USA).
Statistical analysis
The results are presented as mean and standard deviations
throughout the manuscript. Cytokine levels were mea-
sured as “median intensity values”, and the direct readings
were evaluated instead of transformation to pg/ml. The
parameters compared between patients and controls were
subjected to the non-parametric Mann-Whitney U-test.
The proportions of expanded gδ T cells were compared
with the chi square test.
Results
Phenotype of gδ T lymphocytes in peripheral blood
The proportions of gδ+ T cells in PBMC were relatively
low in BD patients and in both disease (TB) and healthy
control (HC) groups (Table 2). Pan gδ+T cells were slightly
increased only in patients with inactive BD (IA-BD) com-
pared to HC (Mean: 4.7 vs. 3.6%, P = 0.029). The differ-
ence of pan gδ+T cells between active BD (A-BD) and
IA-BD patients was not significant. The proportion of
major gδ T cell population in the PB, namely TCRVg9Vδ2
+ T cells (shown with anti-Vδ2 antibody) was similar in all
groups (Table 2). When compared among the pan gδ+
T cells, the dominance of TCRVδ2+ T cells was less
prominent in BD and particularly in the IA-BD group
compared to HC (58.9 and 54 vs. 71.7%, P = 0.04 and P =
0.014, respectively). This significantly lower proportion of
TCRVδ2+ of pan gδ+ T cells was observed in TB as well
(50.7%, compared to HC P = 0.005).
To access the functional status of the gδ T cells, sur-
face expression of several co-stimulatory receptors was
screened on these cells. The immunoglobulin receptor
CD16, discriminating two subsets of TCRVg9Vδ2+ T cells
with distinct functional responses, was evaluated as [7] an
activation receptor for TCRVδ2+ T cells. CD16 expression
on these cells was higher in both in BD patients (including
active and inactive) compared to HC (26.2 vs. 16.6%, P =
0.02). This TCRVδ2+ T cell population expressing CD16
was even more increased in TB group compared to HC
(33.9%, P = 0.001, Figure 1).
When pan gδ+ T cells are analyzed for expression of
NKG2A or NKG2C receptors, the higher fraction of
TCRVg9Vδ2+ T cells expressed inhibitory NKG2A rather
than activating NKG2C in all groups as shown previously
[9] (Table 2). Similar to a previous study [20], the fraction
of NKG2C+ gδ+ T cells varied widely in all groups of this
study. However, a slight increase of activating NKG2C
+gδ+ T cells among the PB lymphocytes was observed in
Table 2 Phenotypic features of gδ T cells in BD, TB patients and healthy controls (HC)
Subtype BD TB HC BD vs. HC TB vs. HC
70 27 26
gδ+ T 4.3 ± 2.2 3.5 ± 2.6 3.6 ± 2.5
TCRVδ2+ T 2.6 ± 1.9 2.2 ± 2.5 2.4 ± 2
TCRVδ2+ T of gδ T 58.9 ± 24.3 50.7 ± 23.8 71.7 ± 25.7 0.04 0.005
CD16+ of TCRVδ2+ T 26.2 ± 19.6 33.9 ± 19.1 16.6 ± 13 0.02 0.001
CCR7- of TCRVδ2+ T 32.2 ± 18.5 27.9 ± 15.9 17.7 ± 9.2 < 0.001 0.014
NKG2A+ gδ+ T 1.8 ± 1.4 1.3 ± 1.6 1.2 ± 0.7
NKG2A+ of gδ+ T 38 ± 20.9 32.6 ± 20.3 39.4 ± 15
NKG2C+ gδ+ T 0.53 ± 0.44 0.64 ± 0.8 0.3 ± 0.3 0.008 0.018
NKG2C+ of gδ T 13.5 ± 11.8 14.3 ± 13.9 11.3 ± 9.3
NKG2D+ gδ+ T 3.4 ± 1.9 2.7 ± 2 2.8 ± 1.4
NKG2D+ of gδ T 77.7 ± 15.3 75.8 ± 17.5 87.5 ± 11.5 0.001 0.004
Mean values ± S.D. are presented. P-values of respective comparisons are listed in left columns.
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the BD group compared to the HC (0.5 vs. 0.3%, P =
0.008). Namely, the NKG2C+ fraction of pan gδ+ T cells
was increased in BD compared to controls without reach-
ing statistical significance (13.5 vs. 11.3%). The relative
increase of NKG2C+ gδ+T cells was also detected in TB
(0.6% of PB lymphocytes, P = 0.018, and 14.3% of gδ+
T cells, Table 2).
TCRVg9Vδ2+ T cells can also be activated through
NKG2D independently of antigen [21] or by ligands of
NKG2D, that is, MICA or MICB, which are often
induced by stress [22]. NKG2D receptors on the gδ T
cells, however, were decreased in patients with BD and
TB compared to HC (77.7 and 75.8 vs. 87.5%, P = 0.001
and 0.004, Figure 2).
CCR7 is used to distinguish tissue-homing effector and
lymph node-homing non-effector memory cells [23].
When expression of CCR7 was investigated, CCR7- of
TCRVδ2+ cells were increased in BD compared to HC
(32.2 vs. 17.7%, P < 0.001) implicating an increase of
effector gδ T cell phenotype in the periphery by losing
their CCR7 [24]. These CCR7- gδ T cells were also more
frequent in PB of TB patients compared to HC (27.9%,
P = 0.014, Figure 1).
These data showed, despite the comparable number of
gδ T cells in BD as in HC, that increased proportions of
CD16+, NKG2C+ or CCR7- gδ+ T cells with an effector
phenotype were evident in BD as well as in TB.
In vitro cytokine and chemokine responses of short-term
gδ+ T cell lines
To evaluate the effector functions, such as in vitro expan-
sion capability and cytokine activity of gδ T cells in BD,
phosphoantigen analog BrHPP was used to stimulate these
cells and responsive cells were propagated with IL-2. From
the gδ T cell cultures of 70 BD and 27 TB patients and 30
HC donors, 55.7% (50% in A-BD and 62.5% in IA-BD),
33.3% and 70% could be expanded up to > 70% TCRVδ2+
at the eighth day in vitro, respectively. The mean expan-
sion ratio of BD patients was lower in A-BD than IA-BD
and in HC without statistical significance. However, this
expandability of cells was significantly lower in TB patients
compared to HC (P = 0.008) (Figure 3). The expanded gδ
T cells were used further in vitro to compare their respon-
siveness to stimuli by cytokine secretion.
When stimulated with phosphoantigens via TCR, var-

















      CD16+                                          CCR7-
%
Figure 1 CD16+ or CCR7-TCRVδ2+ T cells. The proportion of TCRVδ2+ T cells carrying CD16 or lacking CCR7 in the peripheral blood of 70 BD
(38 A-BD, 32 IA-BD), 27 TB patients and 30 HC. The differences of BD and TB with HC were significant (P = 0.02 and P = 0.001, and P < 0.001
and P = 0.014, respectively).
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in gδ T cells [25]. Phosphoantigen reactive gδ T cells
represented a type-1 polarized subset secreting IFN-g and
TNF-a [26]. Expanded gδ T cells of patients and controls
containing over 70% gδ T cells (short-term gδ T cell lines)
were restimulated by TCR and compared for cytokine and
chemokine secretions in culture supernatants from 42 BD,
9 TB patients and 20 HCs. The phosphoantigen re-stimu-
lation induced in these short-term gδ T cell lines to pro-
duce higher levels of IFN-g, GM-CSF, IL-13, TNF-a as
well as CCL4 (MIP1-b) and CCL5 (RANTES) in all patient
and control groups (Additional file 1, Figure S1 shows the
results in HC). Induction of IFN-g and IL-13 production
of short-term gδ T cell lines by TCR (BrHPP) re-stimula-
tion did not differ among groups, whereas GM-CSF,
TNF-a, CCL4 and CCL5 production was lower in BD
compared to HC (P = 0.02, 0.015, 0.05, respectively).
An interaction of TCR- and TLR-signaling is shown to
enhance effector functions of human PB gδ T cells. To
investigate the activating or co-stimulating properties of
TLR3 on gδ T cells, a TLR3 ligand was added to the cells
at the re-stimulation stage to mimic the responses to speci-
fic and non-specific stimulations. The re-stimulation with
TCR and TLR3 agonist simultaneously induced signifi-
cantly lower levels of IFN-g, IL-13, TNF-a, as well as GM-
CSF, CCL4 and CCL5, in BD than in HC (P = 0.008, 0.029
and 0.021, 0.018, 0.012 and 0.044, respectively) (Figure 4).
As 42% of the patients were on immunosuppressive
treatment at the time of blood sampling, we compared
the patients with or without treatment to see the possi-
ble effect of treatment. The responses to TCR stimula-
tion did not show a significant difference between the
groups receiving a treatment or not.
Discussion
gδ T cells have been evaluated in BD in various studies











BD A-BD IA-BD TB HC
P= 0.008 
Figure 3 Ratio of expanded gδ+ T cells. The % ratio of gδ+ T cells
expanded over 70% in 70 total BD (in A-BD and IA-BD), 27 TB
patients and 30 HC. The difference between TB and HC groups was









Figure 2 TCR gδ+ T cells carrying NKG2D. The % of TCR gδ+ T cells carrying NKG2D in the peripheral blood of 70 BD (38 A-BD, 32 IA-BD), 27
TB patients and 30 HC. The differences between BD and TB to HC were significant (P = 0.001 and P = 0.004).
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Figure 4 Production of cytokines with TCR and co-stimulation of TLR3 of gδ T cells. IFN-g, CCL4 and CCL5 as well as GM-CSF, IL-13 and
TNF-a levels with TCR and co-stimulation of TLR3 were significantly lower in BD, including active and inactive patients, than in HC (P = 0.008,
0.012 and 0.044 and 0.018, 0.029 and 0.021, respectively).
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immune activations and functioning as a local defense
response inducing activation of other immune cell popula-
tions. Data such as tissue infiltrations of gδT cells in
erythema nodosum-like lesions of BD patients suggested a
role for gδ T cells in disease pathogenesis. In this study, gδ
T cells are evaluated in BD and as a disease control group
in TB for their activation state and for their functional
activities in response to stimuli.
When the presence of this rare cell population in BD is
compared to healthy individuals, conflicting results have
been published with [13,14,27] and without [16,28]
increased levels in the PB, with a predominantly disease
exacerbation-related increase in recent studies [14,17]. In
the present study, which investigated a relatively higher
number of BD patients, gδ T cells were only slightly
increased in the blood of the patients.
The discrepancy among the previous studies about the
number of gδT cells in PB might be due to the activation
status of the disease, as reflection of local tissue inflam-
mation to PB might be variable due to factors such as the
disease severity or immunosuppressive medications. Even
acute-phase response (erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP)), which is the hallmark
of inflammation, is not a reliable biomarker in BD and
elevated only in relation to a limited number of disease
manifestations, such as arthritis or some skin lesions of
the disease. Similar to our results, in a previous study,
although lesional skin of patients with BD had signifi-
cantly increased gδ T cells, peripheral blood gδ T cells
counts were similar in BD and control groups [29].
Despite the dominance of the TCRVδ2+ subtype among
the gδ T cells in BD patients similar to previous reports
[30], we found a decrease of TCRVδ2+ proportion of gδ
T cells in BD compared to HC. Considering gδ T cells as
an effector cell type against mycobacterial antigens, TB
patients had also relatively low gδ T cells and lower pro-
portions of TCRVδ2+ T cells among pan gδ T cells.
In BD, PB gδ T cells expressed early activation markers
and secreted Th1 and proinflammatory cytokines. Bac-
teria-specific KTH-1 responsive gδ T cell lines have been
demonstrated to be pro-inflammatory, as well. Signifi-
cantly greater proportions of the Vδ1+ and Vδ2+ gδ T cell
subsets were activated in patients with active BD; how-
ever, the balance of activation favored Vδ1+ T cells [31].
In this present study, we have not evaluated Vδ1+ T cells
separately; however, the total number of the gδ T cells
was not increased, suggesting their relatively low
increase, if any, as well. As gδ T cells are more likely to
be tissue resident and relatively rare in the blood, the
phenotypic differences observed between studies may be
related to wide distribution features of cells in systemic
circulation and tissues.
Based on previous data of the activated status of gδ
T cells in BD [17], when phenotypic markers for effector
cells were evaluated, the data revealed an increased acti-
vation status of the gδ T cells in BD and also in TB.
The elevation of FcgRIII (CD16) expression on gδ T
cells was in accordance with some autoimmune diseases,
such as Sjogren’s syndrome or MS [32,33]. Similarly,
effector or central memory T subtypes are proposed for
gδ T cells based on their CCR7 expression [34]. gδ T
cell activation results in an immediate acquisition of sec-
ondary lymphoid tissue-homing capabilities, including
CCR7 expression, which decline afterwards [35]. A rela-
tive increase of gδ T cells without the lymphoid homing
receptor emphasizes effector features of these cells
based on not a recent activation in BD as well as in TB
compared to HC. IFN-g producing gδ T cells in
response to mycobacterium antigen also had mostly an
effector memory cell phenotype of CD45RA- CCR7- in a
recent study [36].
gδ T cells appear to play a predominant role against
mycobacterium tuberculosis infection and produce IFN-g
strongly and early in response to mycobacterial phos-
phoantigens [37,38]. These cells, however, are quantita-
tively and functionally impaired by mycobacterial
infection; the percentage of the Vδ2 subset was found to
be lower in patients with TB than in controls [39] creating
an imbalance between the Vδ1 and the normally predomi-
nant Vδ2+ subsets and Vδ2+ anergy [40]. Reduced circulat-
ing Vg9Vδ2+ T cell effectors in patients with acute
pulmonary tuberculosis resulted in a reduced frequency of
IFN-g-producing cells after stimulation with nonpeptidic
mycobacterial ligands as well [41]. TCRVδ2+ T cells in BD
resemble these cells with down-regulated status in PB.
gδ T cell effector function is also modulated by inhibi-
tory and activating NK receptors. A large fraction of circu-
lating Vg9Vδ2 T cells express MHC class I receptors,
mostly the inhibitory CD94/NKG2A complex. Triggering
of this receptor down-modulates activation of the gδ TCR
and inhibits gδ T cell proliferation and IFN-g and TNF-a
production in response to microbial phosphorylated
ligands representing a mechanism to control self-reactivity
of gδ T cells. Following stimulation with mycobacterial
ligands, the CD94/NKG2A complex has been shown to
rapidly translocate to the cell membrane on Vδ2+ cells,
leading to inhibition of cell activation [42]. In the present
data from BD and TB patients, inhibitory regulation of
Vδ2+ T cells was not up-regulated, but the small number
of activating receptor NKG2C+ gδ T cells were relatively
increased, implicating not a recent activation inducing
NKG2A on δ2+ T cells.
Human Vδ2+ subset of gδ T cells can co-express both
activating and inhibitory NK receptors with FcgRIII
(CD16). CD94/NKG2C complex is functional with IFN-g
production, T cell proliferation and cytolytic activity,
whereas NKG2A expression was found on all gδ T cell
memory subsets, suggesting a crucial role of the inhibitory
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signal provided by this receptor on gδ T cell responses
[20]. In BD and in A-BD a slight increase of activating
NKG2C+gδ T cells has been detected showing an activa-
tion status of the cells, although the other activating recep-
tor, NKG2D, was decreased in BD. Both of these changes
were also detected in the TB group, suggesting similar
functional changes of gδ T cells in both diseases.
Functional alterations in BD were evident as the expan-
sion ratio of gδ T cells was significantly lower in BD and
more so in TB, implicating an unresponsiveness of these
cells for re-stimulation in vitro. That was contrary to the
previous data on BD, as the expansion factor of gδ T cells
was greater in patients with active disease than in those
with inactive disease or in control individuals [17], which
we did not replicate.
Vδ2+ T cells have been shown to regulate other cells by
secretion of cytokines and chemokines, such as CCL4 and
CCL5 [6,25], in response to components of bacterial cell
walls, supporting a role for these cells in the early stages of
the inflammatory responses to many common pathogens.
However, the GM-CSF, CCL4, CCL5 and TNF-a
responses of the expanded cells to TCR stimulation was
lower in BD, especially in IA-BD patients as in TB. This
low response could be the result of the in vitro expansion
step, which may have caused an anergy in these cells. But
also an in vivo exhaustion of gδ T cells could not be ruled
out, although the expandability of the cells points to their
capability to respond to antigenic stimulation in vitro [40].
Although TLR3 is not expressed on the cell surface of
freshly isolated gδ T cells, the co-stimulatory effect of
TLR3 ligation has been shown and it is up-regulated after
TCR-stimulation and increased IFN-g secretion [12]. We
assumed that activation and expansion of gδ T cells
before co-stimulation with TLR3 agonists, could reveal
the effect of TLR3 ligand at the re-stimulation in our sys-
tem. However, the results showed that the short-term
T cell lines of BD patients responded with less cytokine
secretion to TCR and TLR than HC. Similar to our
results, the response of expanded gδ T cells to TLR ligand
co-stimulation has been shown to be somehow lower
than TCR/TLR3 ligand stimulated freshly isolated gδ T
cells [10]. This effect was even more pronounced in BD
patients.
The functional data presented are derived from PB cells
expanded in vitro before testing. Due to the low number
of gδ T cells in PB, in vitro manipulation and stimulation
has been undertaken. However, with the expansion cut-
off, we also had to measure the activity of 30% non-gδ
T cells, which could not be avoided and limits the inter-
pretation of this functional data.
The results only represent a subset of gδ T cells as
mainly Vg9Vδ2 T cells are responding to phosphoantigens
and expand in culture. This subgroup has become the
most widely studied gδ T cell population as they are
readily accessible in human blood, easy to culture and
expand in vitro and are of direct relevance for infection
[43]. Another disadvantage of in vitro stimulation with
phosphoantigens may be the induction of inhibitory recep-
tors on gδ T cells, which may modulate their response in
disease state differentially than HC [44].
The activation of gδ T cells can be cytolytic or inflam-
matory by secretion of cytokines [45]. Previous studies
pointed to a role of activated gδ T cells in BD [17,31,46].
The present study did not provide evidence for an
increase of gδ T cells in active BD patients, although
functional changes implicated by surface receptors are
shown in BD.
A major limitation of our study is the assessment of gδ
T cells function with limited stimulation in an in vitro
culture system. Other PB cell subsets and cytokines/che-
mokines might influence the response of gδ T cells. With
different methodology, such as single-cell experiments
and measurement of mRNA expressions, role and func-
tion of gδ T cells in BD pathogenesis might be further
clarified.
Conclusions
In the present study no increase of gδ T cells was
detected in active BD patients. However, based on surface
receptors on gδ T cells, functional changes of these cells
were implicated. When TCRVδ2+ T cells were expanded
and tested for the response to TCR and TLR stimula-
tions, cytokine and chemokine secretions were found
impaired in BD.
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